Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | PTPRA | P18433 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20330203 | 0.86 | POLB (0.48) | CYP1A2RAB9AALDH1A1NPC1PTPRA | |
| SCHEMBL12017873 | 0.82 | POLB (0.51) | CYP1A2RAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL6302771 | 0.82 | CYP1A2 (0.59) | CYP1A2ALDH1A1PTPRASMN1; SMN2TSHR | |
| SCHEMBL1992815 | 0.80 | KEAP1 (0.47) | CYP1A2RAB9AALDH1A1NPC1PTPRA | |
| SCHEMBL25139855 | 0.80 | CYP1A2 (0.60) | CYP1A2ALDH1A1PTPRASMN1; SMN2LMNA | |
| SCHEMBL28567667 | 0.79 | PARP10 (0.43) | CYP1A2RAB9AALDH1A1NPC1PTPRA | |
| SCHEMBL28567669 | 0.79 | PARP10 (0.43) | CYP1A2RAB9AALDH1A1NPC1PTPRA | |
| SCHEMBL10620852 | 0.79 | PTPRA (0.70) | CYP1A2RAB9AALDH1A1NPC1PTPRA | |
| SCHEMBL29828134 | 0.79 | ALDH1A1 (0.61) | CYP1A2RAB9AALDH1A1NPC1PTPRA | |
| SCHEMBL211090 | 0.79 | ALDH1A1 (0.61) | CYP1A2RAB9AALDH1A1NPC1PTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405453-B1 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) | 2024-05-29 | — | — | EP | claimed |
| CN-108884032-B | Method for preparing poly (carbonate-etherimide) compounds | PTT全球化学股份有限公司 | 2021-10-15 | — | — | CN | claimed |
| US-10759904-B2 | Method for preparing poly(carbonate-etherimide) compound | PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) | 2020-09-01 | — | — | US | claimed |
| US-20190202980-A1 | METHOD FOR PREPARING POLY(CARBONATE-ETHERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) | 2019-07-04 | — | — | US | claimed |
| EP-3405453-A2 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT Global Chemical Public Company Limited (TH) | 2018-11-28 | — | — | EP | claimed |
| EP-3405453-B1 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) | 2024-05-29 | — | — | EP | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| CN-101402537-A | Uses of 2-pyridine-beta ketone compounds | GUANGZHOU INST BIOMED & HEALTH (CN) | 2009-04-08 | — | — | CN | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CYP1A2 2139/4885RAB9A 2463/4885ALDH1A1 1144/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP1A2 2139/4885RAB9A 2463/4885ALDH1A1 1144/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CYP1A2 2139/4885RAB9A 2463/4885ALDH1A1 1144/4885 |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CYP1A2 2942/4885RAB9A 2106/4885ALDH1A1 3393/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | CYP1A2 138/4885RAB9A 2087/4885ALDH1A1 2338/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CYP1A2 138/4885RAB9A 2087/4885ALDH1A1 2338/4885 |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CYP1A2 3939/4885RAB9A 2672/4885ALDH1A1 4405/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | CYP1A2 2958/4885RAB9A 4230/4885ALDH1A1 430/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP1A2 2139/4885RAB9A 2463/4885ALDH1A1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.